[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrauterine-growth-restriction-iugr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrauterine-growth-restriction-iugr":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100640687","estimation-of-fetal-weight-by-measuring-abdominal-circumference-abdominal-subcutaneous-soft-tissue-thickness-femur-length-and-mid-thigh-soft-tissue-thickness-100640687",false,"NCT07575152","Estimation of Fetal Weight by Measuring Abdominal Circumference, Abdominal Subcutaneous Soft Tissue Thickness, Femur Length and Mid-thigh Soft Tissue Thickness","Estimation of Fetal Weight by Measuring Abdominal Circumference, Abdominal Subcutaneous Soft Tissue Thickness, Femur Length and Mid-thigh Soft Tissue Thickness: Cross Sectional Study.","Inclusion Criteria:\n\n1. Singleton Gestation.\n2. Gestational Age: Participants must be at a term ≥ 37 weeks\n3. Timing of Examination: Sonographic EFW must be performed within 48 -72 hours prior to delivery.\n4. Welling to share in the study.\n\nExclusion Criteria:\n\n1. Fetal Anomalies.\n2. Amniotic Fluid Disorders: oligohydramnios or polyhydramnios\n3. Maternal morbid obesity (BMI \\> 40 kg\u002Fm2)\n4. Maternal medical disorders: as diabetes, hypertension, systemic lupus erythromatosis or others affecting fetal growth\n5. Fetal Hydrops\n6. Fetal Malpresentation\n7. Fetal growth restriction",true,"FEMALE","18 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","Traditional methods for estimating fetal weight (EFW) often miss the mark because they focus on bone and circumference while ignoring fetal fat. This study proposes a more inclusive formula to fix that. Current models (using BPD, HC, AC, and FL) are the standard but suffer from high observer variability. These formulas struggle at the extremes (macrosomia or growth restriction) and fail to account for fetal adiposity, which makes up 10-12% of a newborn's mass. The study introduces a novel formula that moves beyond simple bone measurements by integrating Soft Tissue Thickness (STT). By accounting for a broader range of biological variants and fat distribution, this new model aims to provide a non-inferior, more precise predictive value for fetal weight compared to traditional methods.",[25,26,27],"Fetal Macrosomia","Intrauterine Growth Disorders (IUGR and Macrosomia)","Intrauterine Growth Restriction (IUGR)",[29,30,31,32,33,34],"fetal weight estimation","fetal soft tissue thickness","Macrosomia","fetal growth restriction","mid-thigh soft tissue thickness","fetal abdominal soft tissue thickness","NOT_YET_RECRUITING","2026-05-07",{"date":38,"type":39},"2026-05-12","ACTUAL",{"date":41,"type":21},"2026-07-01",{"date":43,"type":21},"2028-07-30",{"name":45,"class":46},"Assiut University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":73,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100613200","prior-study-pre-eclampsia-risk-in-oocyte-recipients-100613200","NCT07263490","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.","PRIOR","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 35 kg\u002Fm2\n* Normal wet smear within the past three years\n* Both nulli- and multiparous\n* Singletons and multiple gestations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 35 kg\u002Fm2\n* HIV\u002F hepatitis\n* Essential hypertension\n* Chronic kidney disease\n* Undiagnosed vaginal bleeding\n* Uterine malformations\n* Persisting ovarian cysts\n* Tumors in hypothalamus, pituitary, thyroid, or adrenal glands.\n* Previous breast cancer\n* Known BRCA 1 or 2 gene\n* Unregulated thyroid disease\n* Cardiovascular disease\n* Breast feeding\n* Present or previous chemotherapy\u002Fradiation therapy\n* Present or previous malignant disease\n* Smoking\n* Alcohol\u002Fdrug abuse",{"count":56,"type":21},462,"The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.\n\nParticipants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.",[59,60,61,62,63,64,65,66,67,68,69,70,71,27,72],"Pre-eclampsia","Oocyte Donation","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia; Mild","Pre-Eclampsia, Severe","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","ART","Neonatal Morbidity","Neonatal Mortality","Placental Abruption","Gestational Diabetes","Preterm Labor","Post-partum Hemorrhage (PPH)","Hypertensive Disorders of Pregnancy",[59,74,65,75,76,77,78],"Preeclampsia","Gestational hypertension","Oocyte donation","Egg donation","Gamete donation","RECRUITING","2026-04-07",{"date":82,"type":39},"2026-04-13",{"date":84,"type":39},"2024-10-21",{"date":86,"type":21},"2028-06-01",{"name":88,"class":46},"Copenhagen University Hospital, Hvidovre",6,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100600552","phase-2-statin-intervention-for-severe-early-onset-placental-insufficiency-statin-pre-trial-100600552","NCT07098975","Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial)","Statin Intervention for Severe Early-Onset Placental Insufficiency: A Randomized Controlled Trial Assessing Daily Administration as a Treatment Strategy (STATIN-PRE Trial)","STATIN-PRE","Inclusion Criteria:\n\n* Singleton fetus.\n* Between 24+0 to 29+6 weeks of gestation at the inclusion.\n* Early-onset severe PE: women with a diagnosis of severe-preterm PE who are candidates for expectant management and have no clinical indication for immediate delivery, based on the clinical assessments of the attending doctors.\n\nAnd\u002For\n\n* IUGR: Diagnosis of early onset IUGR according to the SMFM classification with umbilical artery Doppler with absent\u002Freversed diastolic flow; or estimated fetal weight \\\u003C10th percentile plus pulsatility index (PI) of umbilical artery Doppler \\>95th percentil.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Established maternal or fetal compromise that necessitated immediate delivery\n* Abnormal karyotype, structural abnormalities, or congenital infections.\n* Treatment with pravastatin or other statins prior to inclusion.\n* Lactose intolerance",{"count":99,"type":21},154,"INTERVENTIONAL",[102],"PHASE2","In pregnancies with placental insufficiency, the only available treatment is close monitoring to determine the point at which the risks of preterm birth for the baby are lower than the risks of continuing the pregnancy. Therefore, safely prolonging pregnancy is the current management goal for this condition.\n\nStatins, such as pravastatin, are approved and marketed drugs used to prevent cardiovascular disease. Recent studies suggest that statins may help treat pregnancy complications and prolong pregnancy, thereby avoiding extreme prematurity and improving long-term health outcomes for both mother and baby.\n\nPrevious clinical trials have shown the ability of statins to stabilize angiogenic factors, thus reducing obstetric complications associated with placental insufficiency. In 2015, a study reported that pravastatin was effective in stabilizing blood pressure and reducing proteinuria associated with preeclampsia. More recently, in 2020, it was demonstrated that in pregnant women with fetal growth restriction treated with pravastatin, the sFlt-1\u002FPlGF ratio was lower than in untreated women, indicating a slower progression of placental insufficiency.\n\nThis study proposes administering a daily dose of 40 mg of pravastatin between 24 and 29.6 weeks of gestation to mothers diagnosed with preeclampsia and\u002For fetal growth restriction. One group of women will receive the medication, while another group will receive a visually identical but inactive pill (a placebo), allowing us to determine whether any observed improvement in pregnancy is attributable to the medication. Assignment to the treatment or placebo group will be random, and neither the mothers nor the healthcare professionals caring for them will know which group they are in.\n\nThe investigators also aim to examine whether this intervention during pregnancy protects the cardiovascular system. For this reason, the investigators will assess both the mother and the baby six months after birth using an ultrasound of the heart and blood vessels, and the investigators will also perform a blood test on the mothers. Additionally, the investigators want to explore the needs and expectations of women who experience these complications during pregnancy and postpartum, so that their stories can guide us in finding answers and solutions that are as personalized as possible to the real needs of families. After the visit at six months postpartum, yhe investigators will follow up with annual phone calls over the next four years to check on the participants' health and their baby's. During each call, the investigators will review the participant's health status and talk about how the participant is feeling. All of this will help us ensure that the treatment does not cause any long-term issues and will improve future care for other mothers and babies.\n\nA total of 154 pregnant women are expected to be included in order to meet the study's objectives.",[105,27,106],"Preeclampsia (PE)","Placental Insufficiency",[74,108,106,109,110],"Intrauterine growth restriction","statins","Pravastatin","2026-02-19",{"date":113,"type":39},"2026-02-23",{"date":115,"type":39},"2026-01-14",{"date":117,"type":21},"2028-07",{"name":119,"class":46},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",2]